Atlas Trials

The Role of Ruxolitinib in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Neoplasm

Clinical trial NCT03558607 · UNKNOWN

Trial details

NCT number
NCT03558607
Sponsor
Seoul National University Hospital
Status
UNKNOWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Disorder
Start date
2018-05-17
Primary completion
2022-04-30
Enrollment
17

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.